Blog · Consumer · Published 2026-08-09
Medicare's ~$50 Obesity-Med Tier: What It Means If You've Been Paying Cash for Compounded GLP-1s
As of July 1, 2026, Medicare's obesity-medication coverage phase-in reached a tier where qualifying patients pay roughly $50 per month for covered FDA-approved products — including, per the 2026 expansions, options like Zepbound and the newly approved oral Foundayo. For any Medicare-eligible reader currently paying cash in the compounded market this site tracks ($145–$449 effective across categories), the arithmetic is blunt: a ~$50 covered brand product beats every cash figure here. Coverage is criteria-bound — qualifying diagnoses, plan formularies, and prior authorization apply — but the order of operations has permanently changed: check the coverage door before shopping the cash market, not after.
How to actually run the check
Three steps, all free. First, confirm your plan's 2026 formulary lists an obesity medication and read its criteria — BMI thresholds, comorbidity documentation (sleep apnea and cardiovascular indications open doors that "weight loss" language sometimes doesn't), and any step requirements. Second, have your prescriber file on the strongest applicable indication with documentation attached; initial denials are common and appealable. Third, price the copay for the calendar year — the ~$50 figure applies to qualifying patients on covered products, and plan-level variation is real. If the door opens, the compounded market's price case ends for you; if it stays shut, the cash market remains, and this site's normalized figures are how to shop it.
What this does not change
Compounded semaglutide and tirzepatide are not FDA approved and are not covered by this expansion — Medicare's tier applies to approved products only, which is precisely why the compounded-vs-brand comparison keeps the categories separate. Nor does coverage eligibility make cash figures irrelevant for everyone: non-qualifying patients, excluded plans, and coverage gaps keep a real cash market, where the August price check ($145.00/$186.00 captured floors) and the pricing-literacy guide apply unchanged. The update here is sequence, not substance: coverage first, cash second, and never the reverse by default.
Frequently asked questions
Does Medicare cover compounded GLP-1s?
No — the 2026 coverage expansion applies to FDA-approved obesity medications for qualifying patients. Compounded products are not FDA approved and sit outside it.
Who qualifies for the ~$50 Medicare tier?
Patients meeting plan criteria — qualifying diagnoses and formulary rules apply, and prior authorization is common. Indications like sleep apnea or cardiovascular disease can open doors weight-loss language doesn't; confirm against your plan's 2026 formulary.
Should I stop paying cash for compounded GLP-1s if I'm on Medicare?
Run the coverage check first: a ~$50 covered copay beats every cash figure this site tracks. If your plan's criteria exclude you, the cash market — compounded and brand self-pay — remains, priced on the site's normalized figures.
Primary sources
Coverage details derive from CMS/HHS materials on the 2026 obesity-medication phase-in and plan documentation; copays vary by plan and eligibility. Brand-product context per manufacturer program pages and FDA announcements.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.